The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Selinexor combination regimens reduce toxicity
The current dosing and schedule of selinexor for the treatment of multiple myeloma is challenging for patients. Here, Sagar Lonial, MD, FACP, Winship Cancer Institute at Emory University, Atlanta, GA, explains how different combination regimens are meaning that the dose of selinexor can be lowered, leading to a reduced GI toxicity and the ability to keep patients on the agent for longer. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
